Prognostic significance of the metastatic lymph node ratio for survival in colon cancer

Journal of B.U.ON.

Volumn 16, Issue 3, 2011, Pages 478-485

  Tuna, S ^a   Dalkilic Calis, Mehtap ^b   Sakar, B ^c   Aykan, F ^c   Camlica, H ^c   Topuz, E ^c  

^a ATATURK TRAINING AND RESEARCH HOSPITAL   (Turkey)

^b SISLI ETFAL TRAINING AND RESEARCH HOSPITAL   (Turkey)

^c ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Colon cancer; Metastatic lymph node ratio; Prognostic significance; Survival

Indexed keywords

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER STAGING; CANCER SURVIVAL; COLON CANCER; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROGNOSIS; RETROSPECTIVE STUDY; SEX DIFFERENCE;

ADULT; AGED; AGED, 80 AND OVER; COLONIC NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; RETROSPECTIVE STUDIES;

EID: 80053939355     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Jemal A, Tiwari RC, Murray T et al. Cancer Statistics, 2004. CA Cancer J Clin 2004; 54: 8-29.
2. Steinberg SM, Barkin JS, Kaplan RS, Stablein DM. Prognostic indicators of colon tumors: Gastrointestinal Tumor Study Group experience. Cancer 1986; 57: 1866-1870. (Pubitemid 16112004)
3. Griffin MR, Bergstralh EJ, Coffey RJ et al. Predictors of survival after curative resection of carcinoma of the colon and rectum. Cancer 1987; 60: 2318-2324. (Pubitemid 17153502)
4. Hermanek P, Wiebelt H, Riedl S et al. Long-time results of surgical therapy for colorectal cancer: results of the German Study Group for Colorectal Cancer (SGCRC). Chirurg 1994; 65: 287-297.
5. Newland RC, Chapuis PH, Pheils MT, McPherson JG. The relationship of survival to staging and grading of colorectal carcinoma: a prospective study of 503 cases. Cancer 1981; 47: 1424-1429. (Pubitemid 11090512)
6. Sigurdson ER. Lymph node dissection: is it diagnostic or therapeutic? J Clin Oncol 2003; 21: 965-967. (Pubitemid 46594122)
7. Joseph NE, Sigurdson ER, Hanlon AL et al. Accuracy of determining nodal negativity in colorectal cancer on the basis of the number of nodes retrieved on resection. Ann Surg Oncol 2003; 10: 213-218. (Pubitemid 40486952)
8. Le Voyer TE, Sigurdson ER, Hanlon AL. Colon cancer survival is associated with increasing number of lymph nodes analyzed: a secondary survey of intergroup trial INT-0089. J Clin Oncol 2003; 21: 2912-2919. (Pubitemid 46621841)
9. Berger AC, Sigurdson ER, Le Voyer TE et al. Colon cancer survival is associated with decreasing ratio of metastatic to examined lymph nodes. J Clin Oncol 2005; 23: 8706-8712. (Pubitemid 46211514)
10. Bando E, Yonemura Y, Taniguchi K et al. Outcome of ratio of lymph node metastasis in gastric carcinoma. Ann Surg Oncol 2002; 9: 775-784.
11. Lim W, Olschwang S, Keller JJ et al. Relative frequency and morphology of cancers in STK11 mutation carriers. Gastroenterology 2004; 126: 1788-1794. (Pubitemid 38736344)
12. Mandel JS, Church TR, Ederer F et al. Colorectal cancer mortality: Effectiveness of biennial screening for fecal occult blood. J Nat Cancer Inst 1999; 91: 434-437. (Pubitemid 29128279)
13. Lieberman DA, Weis DG, Bond JH et al. Use of colonoscopy to screen asymptomatic adults for colorectal cancer. Veterans Affairs Cooperative Study Group 380. N Engl J Med 2000; 343: 162-168. (Pubitemid 30489212)
14. Turini ME, Dubois RN. Primary prevention: Phytoprevention and chemoprevention of colorectal cancer. Hematol Oncol Clin North Am 2002; 16: 811-840. (Pubitemid 35215826)
15. Steinbach G, Lynch PM, Philips RK et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2004; 351: 1946-1952. (Pubitemid 30419089)
16. Topol EJ. Failing the public health - Rofecoxib, Merck, and the FDA. N Engl J Med 2004; 351: 1707-1709. (Pubitemid 39383201)
17. Solomon SD, McMurray JJ, Pfeffer MA et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005; 352: 1071-1080. (Pubitemid 40365348)
18. Moertel CG, Fleming TR, Macdonald JS et al. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med 1995; 122: 321-326.
19. Porschen R, Bermann A, Löffler T et al. Fluorouracil plus leucovorin as effective adjuvant chemotherapy in curatively resected stage III colon cancer: results of the trial adjCCA-01. J Clin Oncol 2001; 19: 1787-1794. (Pubitemid 32230881)
20. Saltz LB, Meropol NJ, Loehrer PJ Sr et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004; 22: 1201-1208. (Pubitemid 41079832)
21. Cunningham D, Humblet Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 51: 337-345. (Pubitemid 38944402)
22. Engstrom PF, Benson AB 3rd, Chen YJ et al. Colon cancer clinical practice guidelines in oncology. J Natl Compr Canc Netw 2005; 3: 468-491. (Pubitemid 44265422)
23. Swanson RS, Compton CC, Stewart AK, Bland KI. The prognosis of T3N0 colon cancer is dependent on the number of lymph nodes examined. Ann Surg Oncol 2003; 10: 65-71.
24. Bui L, Rempel E, Reeson D, Simunovic M. Lymph node counts, rates of positive lymph nodes, and patient survival for colon cancer surgery in Ontario, Canada: a population-based study. J Surg Oncol 2006; 93: 439-445. (Pubitemid 44651266)
25. Berger AC, Watson JC, Ross EA, Hoffman LE. The metastatic/examined lymph node ratio is an important prognostic factor after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am Surg 2004; 70: 235-240.
26. Van der Wal BC, Butzelaar RM, van der Meij S, Boermeester MA, Axillary lymph node ratio and total number of removed lymph nodes: predictors of survival in stage I and II breast cancer. Eur J Surg Oncol 2002; 9: 775-784.
27. Johnson MP, Porter AG, Ricciardi R, Baxter NN. Increasing negative lymph node count is independently associated with improved long-term survival in stage IIIB and IIC colon cancer. J Clin Oncol 2006; 24: 3570-3575. (Pubitemid 46630528)
28. Kobayashi H, Ueno H, Hashiguchi Y, Mochizuki H. Distribution of lymph node metastasis is a prognostic index in patients with stage III colon cancer. Surgery 2006; 139: 516-22.
29. Schumacher P, Dineen S, Barnett JC, Fleming J, Anthony T. The metastatic lymph node ratio predicts survival in colon cancer. Am J Surg 2007; 194: 827-832. (Pubitemid 350086537)
30. Lee HY, Choi HJ, Park KJ et al. Prognostic significance of metastatic lymph node ratio in node positive colon carcinoma. Ann Surg Oncol 2007; 14: 1712-1717.
31. Ogata Y, Torigoe S, Matano K et al. Prognostic factors after potentially curative resection in stage II or III colon cancer. Kurume Med J 2005; 52: 67-71. (Pubitemid 43251063)
32. Burton S, Norman AR, Brown G et al. Predictive poor prognostic factors in colonic carcinoma. Surg Oncol 2006; 15: 71-78. (Pubitemid 44765207)